 Jennifer L. McNeer
Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 12 | 2022 | 305 | 4.490 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2019 | 36 | 1.790 |
Why?
| | Hematologic Diseases | 3 | 2017 | 78 | 1.350 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2019 | 811 | 1.140 |
Why?
| | Immunotherapy | 2 | 2020 | 571 | 1.120 |
Why?
| | Central Nervous System Diseases | 1 | 2022 | 51 | 0.950 |
Why?
| | Central Nervous System Neoplasms | 1 | 2022 | 81 | 0.880 |
Why?
| | Ploidies | 1 | 2019 | 37 | 0.780 |
Why?
| | Child | 15 | 2022 | 6710 | 0.710 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2017 | 63 | 0.660 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2018 | 265 | 0.600 |
Why?
| | Immune System Diseases | 1 | 2015 | 24 | 0.600 |
Why?
| | Burkitt Lymphoma | 1 | 2014 | 34 | 0.550 |
Why?
| | Adolescent | 17 | 2021 | 9105 | 0.550 |
Why?
| | Arsenicals | 2 | 2010 | 42 | 0.520 |
Why?
| | Oxides | 2 | 2010 | 49 | 0.520 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2014 | 114 | 0.510 |
Why?
| | Young Adult | 16 | 2021 | 5954 | 0.480 |
Why?
| | Folic Acid | 1 | 2011 | 45 | 0.460 |
Why?
| | Carnitine | 2 | 2021 | 17 | 0.420 |
Why?
| | Asparaginase | 2 | 2021 | 24 | 0.420 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2010 | 49 | 0.420 |
Why?
| | Child, Preschool | 8 | 2019 | 3752 | 0.400 |
Why?
| | Injections, Spinal | 2 | 2022 | 48 | 0.390 |
Why?
| | Humans | 31 | 2022 | 82932 | 0.390 |
Why?
| | Communicable Diseases | 1 | 2010 | 69 | 0.390 |
Why?
| | C-Reactive Protein | 1 | 2010 | 192 | 0.390 |
Why?
| | Antineoplastic Agents | 5 | 2021 | 2358 | 0.360 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 2308 | 0.360 |
Why?
| | Infant | 5 | 2019 | 3085 | 0.360 |
Why?
| | Neoplasms | 3 | 2020 | 2669 | 0.350 |
Why?
| | Glucocorticoids | 1 | 2010 | 358 | 0.340 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 820 | 0.330 |
Why?
| | Polyethylene Glycols | 2 | 2021 | 395 | 0.330 |
Why?
| | Remission Induction | 5 | 2019 | 712 | 0.320 |
Why?
| | Translocation, Genetic | 2 | 2016 | 263 | 0.270 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1179 | 0.260 |
Why?
| | Male | 18 | 2021 | 41802 | 0.250 |
Why?
| | Female | 18 | 2021 | 44644 | 0.240 |
Why?
| | Prognosis | 4 | 2020 | 3694 | 0.240 |
Why?
| | Etoposide | 2 | 2019 | 198 | 0.230 |
Why?
| | Retrospective Studies | 5 | 2022 | 7582 | 0.230 |
Why?
| | Cytogenetic Analysis | 2 | 2019 | 73 | 0.220 |
Why?
| | Methotrexate | 1 | 2022 | 260 | 0.220 |
Why?
| | Survivors | 2 | 2020 | 193 | 0.220 |
Why?
| | Neoplasm, Residual | 2 | 2019 | 132 | 0.210 |
Why?
| | Hematologic Neoplasms | 2 | 2016 | 293 | 0.210 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2019 | 661 | 0.200 |
Why?
| | Anthracyclines | 1 | 2019 | 28 | 0.200 |
Why?
| | Infant, Newborn | 3 | 2019 | 2427 | 0.200 |
Why?
| | Postoperative Complications | 1 | 2010 | 2265 | 0.200 |
Why?
| | Leukemia | 1 | 2021 | 296 | 0.190 |
Why?
| | Disease-Free Survival | 2 | 2019 | 1194 | 0.190 |
Why?
| | Recurrence | 1 | 2022 | 1193 | 0.190 |
Why?
| | Hyperbilirubinemia | 1 | 2018 | 20 | 0.190 |
Why?
| | Adult | 12 | 2021 | 25931 | 0.170 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 48 | 0.170 |
Why?
| | Risk Factors | 3 | 2020 | 5396 | 0.170 |
Why?
| | Salvage Therapy | 1 | 2018 | 224 | 0.170 |
Why?
| | Treatment Outcome | 5 | 2018 | 7874 | 0.160 |
Why?
| | Point-of-Care Systems | 1 | 2017 | 133 | 0.160 |
Why?
| | Hodgkin Disease | 1 | 2017 | 166 | 0.160 |
Why?
| | Prevalence | 2 | 2018 | 1259 | 0.160 |
Why?
| | Chronic Disease | 1 | 2020 | 964 | 0.160 |
Why?
| | Escherichia coli Infections | 1 | 2016 | 52 | 0.160 |
Why?
| | Bone Marrow Examination | 1 | 2015 | 53 | 0.150 |
Why?
| | Philadelphia Chromosome | 1 | 2015 | 31 | 0.150 |
Why?
| | Radiotherapy | 1 | 2017 | 337 | 0.150 |
Why?
| | Bacteremia | 1 | 2016 | 117 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 578 | 0.140 |
Why?
| | Survival Rate | 4 | 2021 | 1918 | 0.140 |
Why?
| | Prednisone | 2 | 2017 | 264 | 0.140 |
Why?
| | Guideline Adherence | 1 | 2016 | 225 | 0.140 |
Why?
| | U937 Cells | 2 | 2010 | 33 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2016 | 407 | 0.130 |
Why?
| | Escherichia coli | 1 | 2016 | 621 | 0.130 |
Why?
| | Leukemia, T-Cell | 1 | 2012 | 18 | 0.130 |
Why?
| | Chromosome Aberrations | 1 | 2014 | 397 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2014 | 307 | 0.120 |
Why?
| | Lymphoma, T-Cell | 1 | 2012 | 44 | 0.120 |
Why?
| | Stress, Psychological | 1 | 2016 | 307 | 0.120 |
Why?
| | Pediatrics | 1 | 2017 | 344 | 0.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 936 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2014 | 384 | 0.120 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 31 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2012 | 113 | 0.120 |
Why?
| | Transplantation, Homologous | 2 | 2012 | 1019 | 0.110 |
Why?
| | Dithiothreitol | 1 | 2010 | 28 | 0.110 |
Why?
| | Quality of Life | 1 | 2017 | 1357 | 0.100 |
Why?
| | Acetylcysteine | 1 | 2010 | 76 | 0.100 |
Why?
| | Tretinoin | 1 | 2010 | 125 | 0.100 |
Why?
| | Area Under Curve | 1 | 2010 | 345 | 0.100 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 165 | 0.090 |
Why?
| | Protein Kinases | 1 | 2010 | 223 | 0.090 |
Why?
| | Dexamethasone | 1 | 2010 | 314 | 0.090 |
Why?
| | Enzyme Activation | 1 | 2010 | 737 | 0.090 |
Why?
| | Autophagy | 1 | 2010 | 163 | 0.090 |
Why?
| | Graft vs Host Disease | 1 | 2010 | 336 | 0.090 |
Why?
| | Hematopoietic Stem Cells | 1 | 2010 | 284 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 973 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2010 | 568 | 0.090 |
Why?
| | Transplantation Conditioning | 1 | 2010 | 366 | 0.090 |
Why?
| | ROC Curve | 1 | 2010 | 756 | 0.090 |
Why?
| | Proportional Hazards Models | 1 | 2010 | 870 | 0.090 |
Why?
| | Age Factors | 1 | 2012 | 1913 | 0.090 |
Why?
| | Reactive Oxygen Species | 1 | 2010 | 459 | 0.080 |
Why?
| | Phosphorylation | 1 | 2010 | 1155 | 0.080 |
Why?
| | Induction Chemotherapy | 2 | 2021 | 137 | 0.080 |
Why?
| | Sex Factors | 1 | 2010 | 1090 | 0.080 |
Why?
| | Predictive Value of Tests | 1 | 2010 | 1753 | 0.070 |
Why?
| | Cell Line, Tumor | 1 | 2010 | 2420 | 0.070 |
Why?
| | Genetic Variation | 1 | 2010 | 1357 | 0.060 |
Why?
| | Prospective Studies | 2 | 2021 | 4063 | 0.060 |
Why?
| | United States | 3 | 2021 | 6273 | 0.060 |
Why?
| | Base Sequence | 2 | 2016 | 2426 | 0.060 |
Why?
| | Amino Acid Sequence | 2 | 2016 | 2172 | 0.060 |
Why?
| | Feasibility Studies | 1 | 2021 | 751 | 0.050 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 273 | 0.050 |
Why?
| | Liver Function Tests | 1 | 2018 | 99 | 0.050 |
Why?
| | Vincristine | 1 | 2017 | 113 | 0.040 |
Why?
| | Vinblastine | 1 | 2017 | 109 | 0.040 |
Why?
| | Bleomycin | 1 | 2017 | 106 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1585 | 0.040 |
Why?
| | Chromosome Breakpoints | 1 | 2016 | 15 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2017 | 290 | 0.040 |
Why?
| | Dacarbazine | 1 | 2017 | 112 | 0.040 |
Why?
| | Doxorubicin | 1 | 2017 | 296 | 0.040 |
Why?
| | Needs Assessment | 1 | 2017 | 140 | 0.040 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2016 | 99 | 0.040 |
Why?
| | Longitudinal Studies | 1 | 2020 | 971 | 0.040 |
Why?
| | Marital Status | 1 | 2016 | 40 | 0.040 |
Why?
| | Disease Progression | 1 | 2021 | 1468 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1681 | 0.040 |
Why?
| | Educational Status | 1 | 2016 | 173 | 0.040 |
Why?
| | Ultrasonography | 1 | 2018 | 693 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 200 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2016 | 329 | 0.040 |
Why?
| | Cohort Studies | 1 | 2021 | 2703 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2014 | 122 | 0.030 |
Why?
| | Anxiety | 1 | 2016 | 256 | 0.030 |
Why?
| | Pilot Projects | 1 | 2016 | 829 | 0.030 |
Why?
| | Genes, myc | 1 | 2012 | 39 | 0.030 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2012 | 53 | 0.030 |
Why?
| | Liver | 1 | 2018 | 1240 | 0.030 |
Why?
| | Chromosomes, Human, Pair 8 | 1 | 2012 | 93 | 0.030 |
Why?
| | Depression | 1 | 2016 | 413 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2020 | 3876 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1920 | 0.030 |
Why?
| | Clinical Laboratory Techniques | 1 | 2012 | 80 | 0.030 |
Why?
| | World Health Organization | 1 | 2012 | 98 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2012 | 219 | 0.030 |
Why?
| | Incidence | 1 | 2016 | 1637 | 0.030 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2010 | 7 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2016 | 1419 | 0.030 |
Why?
| | Bone Marrow Cells | 1 | 2012 | 256 | 0.030 |
Why?
| | Time Factors | 1 | 2020 | 5497 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2016 | 1777 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2010 | 194 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2010 | 202 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2010 | 190 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2010 | 1953 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2010 | 1204 | 0.020 |
Why?
| | Aged | 1 | 2021 | 18473 | 0.020 |
Why?
| | Mice | 1 | 2010 | 11106 | 0.010 |
Why?
| | Animals | 1 | 2010 | 26911 | 0.010 |
Why?
|
|
McNeer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|